Matthew Pauls Sells 54,702 Shares of Savara Inc (NASDAQ:SVRA) Stock

Savara Inc (NASDAQ:SVRA) CEO Matthew Pauls sold 54,702 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $3.31, for a total value of $181,063.62. Following the completion of the transaction, the chief executive officer now owns 1,536,379 shares of the company’s stock, valued at approximately $5,085,414.49. This represents a 3.44 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Savara Stock Down 1.2 %

NASDAQ:SVRA opened at $3.22 on Wednesday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. The company has a market capitalization of $552.61 million, a price-to-earnings ratio of -7.49 and a beta of 0.92. Savara Inc has a one year low of $2.82 and a one year high of $5.70. The stock has a 50-day simple moving average of $3.50 and a 200 day simple moving average of $4.00.

Savara (NASDAQ:SVRA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, hitting the consensus estimate of ($0.11). Sell-side analysts predict that Savara Inc will post -0.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. JMP Securities restated a “market outperform” rating and issued a $9.00 target price on shares of Savara in a research note on Tuesday, October 1st. Evercore ISI reissued an “in-line” rating and issued a $5.00 price target (down previously from $7.00) on shares of Savara in a report on Wednesday, November 13th. Finally, HC Wainwright dropped their price objective on Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $10.17.

Hedge Funds Weigh In On Savara

Hedge funds have recently added to or reduced their stakes in the business. Choreo LLC acquired a new stake in shares of Savara during the second quarter worth $59,000. DRW Securities LLC acquired a new stake in Savara during the second quarter worth about $62,000. Virtu Financial LLC bought a new position in Savara in the third quarter worth about $67,000. Principal Financial Group Inc. boosted its stake in Savara by 64.4% in the second quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock valued at $72,000 after acquiring an additional 6,973 shares during the period. Finally, BNP Paribas Financial Markets grew its holdings in shares of Savara by 258.9% during the third quarter. BNP Paribas Financial Markets now owns 25,693 shares of the company’s stock valued at $109,000 after purchasing an additional 18,534 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.